ALVOTECH
“ I believe diversity generates stronger strategy and better risk management , debates , and outcomes ”
GERHARD HELMERICH HEAD OF GLOBAL SUPPLY CHAIN , ALVOTECH
ARIA ® ( golimumab ), Eylea ® ( aflibercept ) and Prolia ®/ Xgeva ® ( denosumab ). “ We have commercialisation agreements with multiple regional partners and have plans to market our biosimilars in at least 90 countries ,” says Helmerich .
So , what about the future ? Where will the company be in five years ’ time ?
“ Our vision is to build a leading global biopharmaceutical company ,” says Helmerich . “ By then we will hopefully have multiple products on the market through our partnerships and will be closer to bringing a robust pipeline of affordable biosimilars to patients around the world .”
Helmerich says Alvotech will continue to pursue its diverse pipeline of biosimilar programmes . “ Our integrated platform and network of world-class partners will allow us to reach patients with more affordable biosimilars , while positively impacting the global healthcare ecosystem .” He says that when the company succeeds in increasing access to these important biologic medicines for patients “ then all our efforts will have been worth it ”. healthcareglobal . com 47